Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peboctocogene camaparvovec - Bayer

Next Previous
Search
Drug Profile

Peboctocogene camaparvovec - Bayer

Alternative Names: AAV-mediated Factor VIII gene therapy; BAY-2599023; DTX-201

Latest Information Update: 23 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dimension Therapeutics
  • Class Antihaemorrhagics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Haemophilia A

Most Recent Events

  • 31 Dec 2022 Ultragenyx Pharmaceutical has patent protection for peboctocogene camaparvovec
  • 11 Dec 2021 Updated adverse events data from a phase-I/II clinical trial in Haemophilia A presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
  • 05 Mar 2021 Phase-I/II development is still ongoing in Haemophilia A in Bulgaria, Germany, France, Netherlands, United Kingdom and USA (IV) (NCT03588299)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top